

Mercedes Robles-Diaz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3527995/publications.pdf>

Version: 2024-02-01

39
papers

1,686
citations

394421
19
h-index

315739
38
g-index

41
all docs

41
docs citations

41
times ranked

1646
citing authors

#	ARTICLE	IF	CITATIONS
1	Phenotypic characterization of idiosyncratic drug-induced liver injury: The influence of age and sex. <i>Hepatology</i> , 2009, 49, 2001-2009.	7.3	266
2	Use of Hy's Law and a New Composite Algorithm to Predict Acute Liver Failure in Patients With Drug-Induced Liver Injury. <i>Gastroenterology</i> , 2014, 147, 109-118.e5.	1.3	248
3	Drug induced liver injury: an update. <i>Archives of Toxicology</i> , 2020, 94, 3381-3407.	4.2	125
4	Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury. <i>Journal of Hepatology</i> , 2016, 65, 532-542.	3.7	115
5	Hepatotoxicity by Dietary Supplements: A Tabular Listing and Clinical Characteristics. <i>International Journal of Molecular Sciences</i> , 2016, 17, 537.	4.1	114
6	Drug-induced liver injury: insights from genetic studies. <i>Pharmacogenomics</i> , 2009, 10, 1467-1487.	1.3	90
7	Herbal and Dietary Supplement-Induced Liver Injuries in the Spanish DILI Registry. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1495-1502.	4.4	83
8	Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry. <i>Journal of Hepatology</i> , 2021, 75, 86-97.	3.7	72
9	Biomarkers in DILI: One More Step Forward. <i>Frontiers in Pharmacology</i> , 2016, 7, 267.	3.5	52
10	Rechallenge in drug-induced liver injury: the attractive hazard. <i>Expert Opinion on Drug Safety</i> , 2009, 8, 709-714.	2.4	47
11	The value of serum aspartate aminotransferase and gamma-glutamyl transpeptidase as biomarkers in hepatotoxicity. <i>Liver International</i> , 2015, 35, 2474-2482.	3.9	47
12	Antibiotic-Induced Liver Toxicity: Mechanisms, Clinical Features and Causality Assessment. <i>Current Drug Safety</i> , 2010, 5, 212-222.	0.6	34
13	Diagnostic and prognostic assessment of suspected drug-induced liver injury in clinical practice. <i>Liver International</i> , 2020, 40, 6-17.	3.9	30
14	Liver injury after methylprednisolone pulses: A disputable cause of hepatotoxicity. A case series and literature review. <i>United European Gastroenterology Journal</i> , 2019, 7, 825-837.	3.8	29
15	Prevention and management of idiosyncratic drug-induced liver injury: Systematic review and meta-analysis of randomised clinical trials. <i>Pharmacological Research</i> , 2021, 164, 105404.	7.1	29
16	Hepatotoxicity induced by coxibs: how concerned should we be?. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1463-1475.	2.4	26
17	Role of Corticosteroids in Drug-Induced Liver Injury. A Systematic Review. <i>Frontiers in Pharmacology</i> , 2022, 13, 820724.	3.5	22
18	Autoantibody presentation in drug-induced liver injury and idiopathic autoimmune hepatitis. <i>Pharmacogenetics and Genomics</i> , 2016, 26, 414-422.	1.5	21

#	ARTICLE	IF	CITATIONS
19	Assessment of Serious Acute and Chronic Idiosyncratic Drug-Induced Liver Injury in Clinical Practice. <i>Seminars in Liver Disease</i> , 2019, 39, 381-394.	3.6	20
20	Role of Ursodeoxycholic Acid in Treating and Preventing Idiosyncratic Drug-Induced Liver Injury. A Systematic Review. <i>Frontiers in Pharmacology</i> , 2021, 12, 744488.	3.5	20
21	Selected ABCB1, ABCB4 and ABCC2 Polymorphisms Do Not Enhance the Risk of Drug-Induced Hepatotoxicity in a Spanish Cohort. <i>PLoS ONE</i> , 2014, 9, e94675.	2.5	19
22	Idiosyncratic drug hepatotoxicity: a 2008 update. <i>Expert Review of Clinical Pharmacology</i> , 2008, 1, 261-276.	3.1	18
23	High Prevalence of Ibuprofen Drug-Induced Liver Injury in Spanish and Latin-American Registries. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 292-294.	4.4	18
24	Clinical Characteristics and Outcome of Drug-Induced Liver Injury in the Older Patients: From the Young-Old to the Oldest-Old. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1147-1158.	4.7	16
25	Lymphocyte Profile and Immune Checkpoint Expression in Drug-Induced Liver Injury: An Immunophenotyping Study. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 1604-1612.	4.7	15
26	Acute hepatitis with autoimmune features after COVID-19 vaccine: coincidence or vaccine-induced phenomenon?. <i>Gastroenterology Report</i> , 2022, 10, goac014.	1.3	15
27	Hepatotoxicity in 2011: advancing resolutely. <i>Revista Espanola De Enfermedades Digestivas</i> , 2011, 103, 472-479.	0.3	12
28	The influence of drug properties and host factors on delayed onset of symptoms in drug-induced liver injury. <i>Liver International</i> , 2018, 39, 401-410.	3.9	10
29	Incidence and prevalence of acute hepatitis E virus infection in patients with suspected Drug-Induced Liver Injury in the Spanish DILI Registry. <i>Liver International</i> , 2020, 41, 1523-1531.	3.9	10
30	Recurrent hepatotoxicity associated with etanercept and adalimumab but not with infliximab in a patient with rheumatoid arthritis. <i>Revista Espanola De Enfermedades Digestivas</i> , 2012, 104, 282-283.	0.3	9
31	Characterizing Drug-Induced Liver Injury With Autoimmune Features. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1844-1845.	4.4	8
32	Serious liver injury induced by Nimesulide: an international collaborative study. <i>Archives of Toxicology</i> , 2021, 95, 1475-1487.	4.2	7
33	Boosting mitochondria activity by silencing MCJ overcomes cholestasis-induced liver injury. <i>JHEP Reports</i> , 2021, 3, 100276.	4.9	5
34	Differential iNKT and T Cells Activation in Non-Alcoholic Fatty Liver Disease and Drug-Induced Liver Injury. <i>Biomedicines</i> , 2022, 10, 55.	3.2	4
35	A New Hepatoprotective Effect of Statins: Are They Always Safe for the Liver?. <i>American Journal of Gastroenterology</i> , 2017, 112, 384-385.	0.4	3
36	Drug-induced liver and skin reactions: In need of a consensus definition. <i>Hepatology</i> , 2017, 65, 391-391.	7.3	3

#	ARTICLE	IF	CITATIONS
37	Reply. Gastroenterology, 2014, 147, 1442.	1.3	0
38	Reply. Gastroenterology, 2015, 148, 452-453.	1.3	0
39	Reply letter to "Editorial: bodybuilders beware" Alimentary Pharmacology and Therapeutics, 2019, 50, 473-473.	3.7	0